SCHEMBL1157308

SCHEMBL1157308

COc1ccc(NCc2cccc(OC)c2O)cc1OC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
KDM4E B2RXH2 5/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ALOX15 P16050 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
GAA P10253 6/20 0.54
POLB P06746 1/20 0.52
PKM P14618 1/20 0.51
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 3/20 0.49
EPHX2 P34913 2/20 0.49
HPGD P15428 3/20 0.49
LMNA P02545 2/20 0.49
NPC1 O15118 1/20 0.49
NFKB1 P19838 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157601 0.88 MEN1 (0.58) MAPTKDM4EMEN1KMT2AALOX15
SCHEMBL1157577 0.84 EPHX2 (0.65) MAPTKDM4EMEN1KMT2AALOX15
SCHEMBL1157311 0.83 POLB (0.53) MAPTKDM4EMEN1KMT2ACYP3A4
SCHEMBL1157360 0.81 EPHX2 (0.67) MAPTKDM4EMEN1KMT2ANPSR1
SCHEMBL27583459 0.80 MAPT (0.47) MAPTKDM4EMEN1KMT2AALOX15
SCHEMBL1157332 0.80 PDE4A (0.58) MEN1KMT2ANPSR1POLBPDE4D
SCHEMBL1157627 0.79 POLB (0.47) MAPTKDM4EGAAPOLBALDH1A1
SCHEMBL4204791 0.79 PDE4D (0.54) POLBEPHX2PDE4DPDE4APDE4B
SCHEMBL1157585 0.78 PDE5A (0.54) MAPTMEN1KMT2ANPSR1GAA
SCHEMBL1157256 0.78 UTS2R (0.57) MAPTKDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
CN-100378075-C Aniline derivatives useful as phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS INC (US) 2008-04-02 CN disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
CN-1688545-A phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARM CORP (US) 2005-10-26 CN disclosed
EP-1539697-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS Memory Pharmaceutical Corporation (US) 2005-06-15 EP disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
CN-1498211-A Aniline derivative using as phosphodiesterase 4 inhibitor ����˹��ҩ�﹫˾ 2004-05-19 CN disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
WO-2004009552-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885KDM4E 332/4885MEN1 3293/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885KDM4E 332/4885MEN1 3293/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885KDM4E 332/4885MEN1 3293/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B MAPT 4102/4885KDM4E 169/4885MEN1 3301/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B MAPT 4102/4885KDM4E 169/4885MEN1 3301/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A MAPT 3913/4885KDM4E 156/4885MEN1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.